NCT02983578 2025-05-06
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
AstraZeneca